FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Evidence |
| Id | Evidence-397478.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Title: Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
Variable in role of population: the study group
Variable in role of exposure: GroupAssignment: Quadpill vs. Candesartan
Variable in role of outcome: Adverse event free and hypertension control at 12 weeks
Statistic: odds ratio (coded as: STATO:0000182 from https://fevir.net/sevco) 0.83
{
"resourceType": "Evidence",
"id": "397478",
"meta": {
"versionId": "4",
"lastUpdated": "2025-09-13T18:19:04.761Z"
},
"language": "en",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://fevir.net/resources/Evidence/397478",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "397478",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"name": "Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan",
"title": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan",
"citeAs": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 397478. Revised 2025-09-13. Available at: https://fevir.net/resources/Evidence/397478. Computable resource at: https://fevir.net/resources/Evidence/397478#json.",
"status": "active",
"author": [
{
"name": "Brian S. Alper, MD, MSPH"
}
],
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatesTo": [
{
"type": "part-of",
"targetReference": {
"reference": "Composition/375280",
"type": "Composition",
"display": "Outcome Measure Report for QUARTET USA Trial"
}
}
],
"description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"display": "the study group"
}
},
{
"variableRole": "exposure",
"observed": {
"reference": "EvidenceVariable/375183",
"type": "EvidenceVariable",
"display": "GroupAssignment: Quadpill vs. Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/375278",
"type": "EvidenceVariable",
"display": "Adverse event free and hypertension control at 12 weeks"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000182",
"display": "odds ratio"
}
]
},
"quantity": {
"value": 0.83
},
"numberAffected": 13,
"sampleSize": {
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed",
"valueUnsignedInt": 53
}
],
"numberOfParticipants": 62,
"knownDataCount": 53
},
"attributeEstimate": [
{
"type": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000196",
"display": "confidence interval"
}
]
},
"level": 0.95,
"range": {
"low": {
"value": 0.22
},
"high": {
"value": 3.16
}
}
},
{
"type": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000700",
"display": "p-value"
}
]
},
"quantity": {
"value": 0.775
}
}
]
}
]
}